Rusfertide's REVIVE Study Highlights 2-Year Efficacy in Polycythemia Vera (PV)

Protagonist Therapeutics, Inc. has unveiled compelling data from its Rusfertide REVIVE study during the American Society of Hematology 2023 Annual Meeting. The study spans two years, demonstrating the lasting efficacy and safety of rusfertide, a hepcidin mimetic, in treating polycythemia vera (PV) patients. The findings showcase significant benefits, including durable hematocrit control, reduced phlebotomy needs, and overall improved patient outcomes.

The study underscores rusfertide's lasting efficacy in treating polycythemia vera (PV), with 69% of patients maintaining durable hematocrit control and remaining phlebotomy-free at 12 weeks. The treatment demonstrates improved and normalized serum ferritin levels, addressing iron deficiency markers, all while maintaining a favorable safety profile with minimal adverse events. This milestone positions rusfertide as a promising option for PV patients, advancing through the Phase 3 VERIFY study for further validation. 

For comprehensive details about VERIFY study click on ClinicalTrials.gov or see the Protagonist Presentation at ASH 2023.